Derek Archila

Philip Nadeau

Raghuram Selvaraju

Seamus Fernandez

Tazeen Ahmad

Joseph Stringer

Whitney Ijem

Jonathan Wolleben

Leland Gershell

Michael Ulz

Paul Matteis

Corinne Jenkins

Corinne Johnson

Dae Gon Ha

Dennis Ding

Jeff Hung

Jon Wolleben

Yuchen Ding

- Rhythm Pharmaceuticals anticipates launching IMCIVREE for Hypothalamic Obesity (HO) **early next year**, targeting a patient population estimated between **5,000 and 10,000**.  **[1649904_tx_380329_3]** **[1649904_tx_380329_4]**  The launch is expected to be more **gradual** than Prader-Willi Syndrome (PWS) but potentially quicker than Bardet-Biedl Syndrome (BBS) initially.  **[1649904_tx_380329_3]** 
- The company is revisiting Prader-Willi Syndrome (PWS) with setmelanotide, conducting an open-label study with higher doses (up to **5 mg**).  **[1649904_tx_380329_7]**  The primary goal for PWS treatment is **5% weight loss**.  **[1649904_tx_380329_7]** **[1649904_tx_380329_8]** 
- Rhythm's next-generation pipeline includes **bivamelagon** (oral), which will advance to Phase 3 for HO, and **RM-718** (weekly), also in development for HO, with the intent to develop both.  **[1649904_tx_380329_10]** 
- The company highlighted that its U.S. formulation patents for IMCIVREE extend through **2034**, providing a strong market position.  **[1649904_tx_380329_1]**

Rhythm Pharmaceuticals Provides Update on IMCIVREE Launch and Pipeline Development

RHYTHM PHARMACEUTICALS (RYTM)